V. Yablokova

发表

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.

K. Krejcy, C. Klade, R. Kralovics, 2020, The Lancet. Haematology.

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups

K. Krejcy, C. Klade, R. Kralovics, 2020, HemaSphere.

A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia – the TEAM‐ET 2·0 trial

C. Klade, H. Gisslinger, N. Tzvetkov, 2019, British journal of haematology.

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

K. Krejcy, C. Klade, R. Kralovics, 2022, Leukemia.

Evidence for Superior Efficacy and Disease Modification after Three Years of Prospective Randomized Controlled Treatment of Polycythemia Vera Patients with Ropeginterferon Alfa-2b Vs. HU/BAT

K. Krejcy, C. Klade, R. Kralovics, 2018, Blood.

Ropeginterferon Alfa-2b Induces High Rates of Clinical, Hematological and Molecular Responses in Polycythemia Vera: Two-Year Results from the First Prospective Randomized Controlled Trial

K. Krejcy, C. Klade, R. Kralovics, 2017 .

Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV)

K. Krejcy, C. Klade, R. Kralovics, 2022, Blood.

Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension

K. Krejcy, C. Klade, R. Kralovics, 2020 .